Health Care & Life Sciences » Pharmaceuticals | Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
52.97 M
Public Float
35.07 M
Dicerna Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.7
Market Cap
$1.01 B
Shares Outstanding
68.32 M
Public Float
45.19 M

Profile

Address
87 Cambridgepark Drive
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.dicerna.com
Updated 07/08/2019
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A.

Financials

View All
Created with Highcharts 5.0.14Dicerna Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.18 63918 63947 93947 93962 83962 83959 51359 51360 04860 04888 85388 853201320142015201620172018020k40k60k80k100k
Created with Highcharts 5.0.14Dicerna Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.00001841842952952 2772 2776 1766 17620132014201520162017201802k4k6k8k

Douglas M. Fambrough
President, Chief Executive Officer & Director
David Michael Madden
Chairman